Alison Gracom, PA
Medical · Irvine, CANPI 1245496843
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $327,936 of the $466,640 with a category attached, or 70.3%. Corcept Therapeutics accounts for 86.5% of it on its own, with 39 other manufacturers making up the rest. Among medical clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 968 payments — averaging $482.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$403K
- Recordati_rare_diseases_inc.$42K
- Xeris Pharmaceuticals, Inc.$15K
- AbbVie$2K
- Novo Nordisk$583
- Lilly USA, LLC$540
- plus $3K from 34 others
What the payments were for
- Consulting fees$20,6904%
- Speaking & faculty fees$327,93670%
- Travel & lodging$99,05121%
- Food & beverage$18,8594%
- Education$1040%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 545 | $403,453 |
| Recordati_rare_diseases_inc. | 39 | $42,331 |
| Xeris Pharmaceuticals, Inc. | 73 | $14,880 |
| AbbVie | 96 | $1,675 |
| Novo Nordisk | 38 | $583 |
| Lilly USA, LLC | 25 | $540 |
| Boehringer Ingelheim | 23 | $537 |
| Merck | 12 | $221 |
| IBSA Pharma Inc. | 7 | $216 |
| AstraZeneca | 12 | $214 |
| Radius Health, Inc. | 9 | $209 |
| Mannkind Corporation | 8 | $171 |
| Amgen(2 entities) | 9 | $165 |
| Idorsia Pharmaceuticals US Inc | 8 | $143 |
| Galderma Laboratories, L.p. | 8 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $139 |
| EUSA Pharma (US) LLC | 3 | $97 |
| Currax Pharmaceuticals LLC | 5 | $91 |
| Eisai Inc. | 4 | $85 |
| Surgenex LLC | 3 | $68 |
| Acella Pharmaceuticals, LLC | 4 | $66 |
| Merz North America, Inc. | 2 | $63 |
| Exact Sciences | 3 | $54 |
| Axsome Therapeutics, Inc. | 2 | $51 |
| GSK | 2 | $49 |
| Vistapharm, Inc. | 2 | $40 |
| Edwards Lifesciences | 2 | $39 |
| Pfizer | 2 | $33 |
| Abbott | 1 | $31 |
| Esperion Therapeutics, Inc. | 2 | $30 |
| Insulet Corporation | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $25 |
| Novartis | 1 | $25 |
| Johnson & Johnson | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Revance Therapeutics, Inc. | 1 | $23 |
| Alfasigma USA, Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $20 |
| Medtronic | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$466,640 in reported general payments places this provider in the 95th percentile of 2,087 medical providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 42 | $56,080 |
| MounjaroTirzepatide | 30 | $44,833 |
| JardianceEmpagliflozin | 24 | $27,552 |
| TrintellixVortioxetine Hydrobromide | 31 | $20,214 |
| BelsomraSuvorexant | 17 | $10,389 |
| Liothyronine Sodium | 99 | $5,107 |
| SynthroidLevothyroxine Sodium | 31 | $3,638 |
| Estradiol (Twice Weekly)Estradiol | 18 | $1,853 |
| Levothyroxine Sodium | 85 | $1,277 |
| Armour ThyroidThyroid,pork | 13 | $1,109 |
| Testosterone | 13 | $1,005 |
| ProgesteroneProgesterone, Micronized | 31 | $944 |
| Omega-3 Acid Ethyl Esters | 13 | $939 |
| Valsartan | 13 | $695 |
| Estradiol | 21 | $630 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $583 | $56,08042 claims |
| Lilly USA, LLCMounjaro | $540 | $44,83330 claims |
| Boehringer IngelheimJardiance | $537 | $27,55224 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $139 | $20,21431 claims |
| MerckBelsomra | $221 | $10,38917 claims |
| AbbVieSynthroid, Armour Thyroid | $1,675 | $4,74744 claims |
| Acella Pharmaceuticals, LLCNp Thyroid | $66 | $55914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 medical providers in California.
Other medical in Irvine
- Kristine NguyenIrvine$26K
- Stacy VencillIrvine$16K
- Nicola LowreyOrange$655K
- Justin LoveLoma Linda$553K
- Jeffrey BonnaudLos Angeles$314K
- Ana TorresLaguna Beach$229K
- Heather ParlettRedlands$168K
- David DoriguzziLancaster$166K
- Deirdre MoxleyFullerton$149K
- Linda RankLadera Ranch$105K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.